Advagene Biopharma Co (ROCO:6709) Cash And Cash Equivalents : NT$37.03 Mil (As of Jun. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Advagene Biopharma Co Cash And Cash Equivalents?

Advagene Biopharma Co's quarterly cash and cash equivalents increased from Jun. 2023 (NT$11.41 Mil) to Dec. 2023 (NT$65.19 Mil) but then stayed the same from Dec. 2023 (NT$65.19 Mil) to Jun. 2024 (NT$37.03 Mil).

Advagene Biopharma Co's annual cash and cash equivalents increased from Dec. 2021 (NT$14.33 Mil) to Dec. 2022 (NT$18.01 Mil) and increased from Dec. 2022 (NT$18.01 Mil) to Dec. 2023 (NT$65.19 Mil).

Advagene Biopharma Co Cash And Cash Equivalents Historical Data

The historical data trend for Advagene Biopharma Co's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advagene Biopharma Co Cash And Cash Equivalents Chart

Advagene Biopharma Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

12.30

121.89

14.33

18.01

65.19

Advagene Biopharma Co Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Cash And Cash Equivalents	Get a 7-Day Free Trial											21.20	18.01	11.41	65.19	37.03

Advagene Biopharma Co Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Advagene Biopharma Co (ROCO:6709) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Advagene Biopharma Co Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Advagene Biopharma Co's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Advagene Biopharma Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Advagene Biopharma Co Ltd (ROCO:6709) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

Sector 1, Neihu Road, 6 Floor, No.308, Neihu District, Taipei, TWN, 114

Website

http://www.advagene.com.tw

Advagene Biopharma Co Ltd is a Taiwan based immune-modulatory platform-based drug developer. The company has completed technology transfer with DCB for detoxified LT Adjuvant Technology Platform. Its product development includes nasal spray influenza vaccine (LT-Flu), allergy vaccines (LT-Allergy), and other vaccines.

Advagene Biopharma Co Headlines

No Headlines